Cover Image
市場調查報告書

茲卡病毒感染疾病:開發中產品分析

Zika Virus Infections - Pipeline Review, H1 2018

出版商 Global Markets Direct 商品編碼 410983
出版日期 內容資訊 英文 200 Pages
訂單完成後即時交付
價格
Back to Top
茲卡病毒感染疾病:開發中產品分析 Zika Virus Infections - Pipeline Review, H1 2018
出版日期: 2018年06月15日 內容資訊: 英文 200 Pages
簡介

茲卡病毒感染主要是由白線斑蚊傳播的病毒引起。茲卡病毒屬於黃病毒科的一員。症狀包括發熱,皮疹,結膜炎,肌肉和關節疼痛,不適和頭痛。風險因素包括在熱帶和亞熱帶地區逗留。茲卡病毒可以透過性交傳染。治療的目的是用點滴和藥物緩解症狀(關節疼痛和發燒)。

本報告提供茲卡病毒感染疾病的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

茲卡病毒感染疾病 概要

治療藥的開發

  • 開發中產品;概要
  • 開發中產品;比較分析

企業開發中的治療藥

大學/機關研究中的治療藥

開發中產品概況

  • 臨床實驗階段的產品
  • 初期階段的產品

企業開發中的產品

大學/研究機關研究中的產品

開發治療藥的企業

  • Bharat Biotech International Ltd
  • Biken Inc
  • BioCryst Pharmaceuticals Inc
  • Biotron Ltd
  • CaroGen Corp
  • Codagenix Inc
  • Ennaid Therapeutics LLC
  • Etubics Corp
  • GeneOne Life Science, Inc.
  • GeoVax Labs Inc
  • Hawaii Biotech Inc
  • Hemispherx Biopharma Inc
  • HSRx Group
  • Humabs BioMed SA
  • Immunovaccine Inc
  • Kineta Inc
  • Mymetics Corp
  • NewLink Genetics Corp
  • Novavax Inc
  • OXIS International Inc
  • PaxVax Inc
  • Pharos Biologicals LLC
  • Plex Pharmaceuticals Inc
  • Prokarium Ltd
  • Protein Sciences Corp
  • Regeneron Pharmaceuticals Inc
  • Replikins Ltd
  • Sanofi Pasteur SA
  • Sirnaomics Inc
  • Spotlight Innovation Inc
  • Starpharma Holdings Ltd
  • 武田藥品工業
  • Tamir Biotechnology Inc
  • TGV-Laboratories
  • Themis Bioscience GmbH
  • Valneva SE
  • Vaxart Inc
  • VaxInnate Corp
  • VBI Vaccines Inc
  • Visterra Inc
  • VLP Therapeutics LLC

治療藥的評估

  • 單劑產品
  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

藥物簡介

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC10518IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Zika Virus Infections - Pipeline Review, H1 2018, provides an overview of the Zika Virus Infections (Infectious Disease) pipeline landscape.

Zika virus infection is caused by a virus transmitted primarily by Aedes mosquitoes. Zika virus is a member of the Flaviviridae family. Symptoms include fever, skin rashes, conjunctivitis, muscle and joint pain, malaise, and headache. Risk factors include being in tropical and subtropical areas. Zika virus can be transmitted through sexual intercourse. Treatment is aimed at relieving symptoms (joint pain and fever) with fluids and medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Zika Virus Infections - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Zika Virus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Zika Virus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Zika Virus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 1, 11, 1, 34, 25 and 2 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 11 and 9 molecules, respectively.

Zika Virus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Zika Virus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Zika Virus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Zika Virus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Zika Virus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Zika Virus Infections (Infectious Disease)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Zika Virus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Zika Virus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • Table of Contents
  • Introduction
  • Zika Virus Infections - Overview
  • Zika Virus Infections - Therapeutics Development
  • Zika Virus Infections - Therapeutics Assessment
  • Zika Virus Infections - Companies Involved in Therapeutics Development
  • Zika Virus Infections - Drug Profiles
  • Zika Virus Infections - Dormant Projects
  • Zika Virus Infections - Discontinued Products
  • Zika Virus Infections - Product Development Milestones
  • Appendix

List of Tables

  • Number of Products under Development for Zika Virus Infections, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Number of Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Products under Development by Companies, H1 2018
  • Products under Development by Companies, H1 2018 (Contd..1), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..2), H1 2018
  • Products under Development by Companies, H1 2018 (Contd..3), H1 2018
  • Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Stage and Target, H1 2018
  • Number of Products by Stage and Mechanism of Action, H1 2018
  • Number of Products by Stage and Route of Administration, H1 2018
  • Number of Products by Stage and Molecule Type, H1 2018
  • Zika Virus Infections - Pipeline by Acuitas Therapeutics Inc, H1 2018
  • Zika Virus Infections - Pipeline by Bharat Biotech Ltd, H1 2018
  • Zika Virus Infections - Pipeline by BioCryst Pharmaceuticals Inc, H1 2018
  • Zika Virus Infections - Pipeline by Biotron Ltd, H1 2018
  • Zika Virus Infections - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018
  • Zika Virus Infections - Pipeline by Cocrystal Pharma Inc, H1 2018
  • Zika Virus Infections - Pipeline by Emergent BioSolutions Inc, H1 2018
  • Zika Virus Infections - Pipeline by Emergex Vaccines Ltd, H1 2018
  • Zika Virus Infections - Pipeline by Ennaid Therapeutics LLC, H1 2018
  • Zika Virus Infections - Pipeline by Etubics Corp, H1 2018
  • Zika Virus Infections - Pipeline by GeneOne Life Science Inc, H1 2018
  • Zika Virus Infections - Pipeline by GeoVax Labs Inc, H1 2018
  • Zika Virus Infections - Pipeline by Gilead Sciences Inc, H1 2018
  • Zika Virus Infections - Pipeline by GT Biopharma Inc, H1 2018
  • Zika Virus Infections - Pipeline by Hawaii Biotech Inc, H1 2018
  • Zika Virus Infections - Pipeline by Heat Biologics Inc, H1 2018
  • Zika Virus Infections - Pipeline by Hemispherx Biopharma Inc, H1 2018
  • Zika Virus Infections - Pipeline by IMV Inc, H1 2018
  • Zika Virus Infections - Pipeline by Johnson & Johnson, H1 2018
  • Zika Virus Infections - Pipeline by Kineta Inc, H1 2018
  • Zika Virus Infections - Pipeline by Moderna Therapeutics Inc, H1 2018
  • Zika Virus Infections - Pipeline by Mymetics Corp, H1 2018
  • Zika Virus Infections - Pipeline by NewLink Genetics Corp, H1 2018
  • Zika Virus Infections - Pipeline by Novalex Therapeutics Inc, H1 2018
  • Zika Virus Infections - Pipeline by Novavax Inc, H1 2018
  • Zika Virus Infections - Pipeline by PaxVax Inc, H1 2018
  • Zika Virus Infections - Pipeline by Plex Pharmaceuticals Inc, H1 2018
  • Zika Virus Infections - Pipeline by Profectus BioSciences Inc, H1 2018
  • Zika Virus Infections - Pipeline by Prokarium Ltd, H1 2018
  • Zika Virus Infections - Pipeline by Replikins Ltd, H1 2018
  • Zika Virus Infections - Pipeline by Sanofi, H1 2018
  • Zika Virus Infections - Pipeline by Sirnaomics Inc, H1 2018
  • Zika Virus Infections - Pipeline by Spotlight Innovation Inc, H1 2018
  • Zika Virus Infections - Pipeline by Stabilitech Biopharma Ltd, H1 2018
  • Zika Virus Infections - Pipeline by Starpharma Holdings Ltd, H1 2018
  • Zika Virus Infections - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
  • Zika Virus Infections - Pipeline by Tamir Biotechnology Inc, H1 2018
  • Zika Virus Infections - Pipeline by TechnoVax Inc, H1 2018
  • Zika Virus Infections - Pipeline by Themis Bioscience GmbH, H1 2018
  • Zika Virus Infections - Pipeline by Theravectys SA, H1 2018
  • Zika Virus Infections - Pipeline by Valneva SE, H1 2018
  • Zika Virus Infections - Pipeline by VBI Vaccines Inc, H1 2018
  • Zika Virus Infections - Pipeline by VLP Therapeutics LLC, H1 2018
  • Zika Virus Infections - Dormant Projects, H1 2018
  • Zika Virus Infections - Discontinued Products, H1 2018

List of Figures

  • Number of Products under Development for Zika Virus Infections, H1 2018
  • Number of Products under Development by Companies, H1 2018
  • Number of Products under Development by Universities/Institutes, H1 2018
  • Number of Products by Targets, H1 2018
  • Number of Products by Stage and Targets, H1 2018
  • Number of Products by Mechanism of Actions, H1 2018
  • Number of Products by Stage and Mechanism of Actions, H1 2018
  • Number of Products by Routes of Administration, H1 2018
  • Number of Products by Stage and Routes of Administration, H1 2018
  • Number of Products by Molecule Types, H1 2018
  • Number of Products by Stage and Molecule Types, H1 2018
Back to Top